Steatosis in Liver Transplantation: Current Limitations and Future Strategies

Transplantation

Volumn 103, Issue 1, 2019, Pages 78-90

  Linares, Ivan ^a,b,c   Hamar, Matyas ^a,d   Selzner, Nazia ^e   Selzner, Markus ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Universidad de Guadalajara   (Mexico)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; CENICRIVIROC; ELAFIBRANOR; LIRAGLUTIDE; OBETICHOLIC ACID; PIOGLITAZONE; SELONSERTIB;

ADVERSE OUTCOME; ARTICLE; CLINICAL PRACTICE; CLINICAL STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; GRAFT FAILURE; GRAFT PERFUSION; GRAFT RECIPIENT; HUMAN; INTESTINE ABSORPTION; INTESTINE FLORA; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIVER DONOR; LIVER PERFUSION; LIVER PROTECTION; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; VENOUS SYSTEMIC OXYGENATED PERSUFFLATION; ALLOGRAFT; GRAFT REJECTION; LIVER; LIVER CIRRHOSIS; ORGAN PRESERVATION; PATHOLOGY; PATIENT SELECTION; PERFUSION; PRACTICE GUIDELINE; PROCEDURES; STANDARDS; TRANSPLANTATION; UNITED STATES;

ALLOGRAFTS; GRAFT REJECTION; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NON-ALCOHOLIC FATTY LIVER DISEASE; ORGAN PRESERVATION; PATIENT SELECTION; PERFUSION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TISSUE AND ORGAN HARVESTING; UNITED STATES;

EID: 85059147320     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000002466     Document Type: Article

References (99)

1. Sherif ZA, Saeed A, Ghavimi S, et al. Global epidemiology of nonalcoholic fatty liver disease and perspectives on US minority populations. Dig Dis Sci. 2016;61:1214-1225.
2. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middleaged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124-131.
3. HalesCM, FryarCD, CarrollMD, et al. Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007-2008 to 2015-2016. JAMA. 2018;319:1723-1725.
4. Wang Y, Beydoun MA, Liang L, et al. Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity (Silver Spring). 2008;16:2323-2330.
5. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.
6. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11-20.
7. IbrahimSH, Hirsova P,Gores GJ. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. Gut. 2018;67:963-972.
8. Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: prevalence and impact on world health. Hepatology. 2016;64:19-22.
9. Lonardo A, Ballestri S, Guaraldi G, et al. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease-evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol. 2016;22:9674-9693.
10. Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62:1723-1730.
11. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547-555.
12. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67:328-357.
13. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, Vitamin E, or placebo for nonalcoholic steatohepatitis.NEngl J Med. 2010;362:1675-1685.
14. Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-and-, induces resolution of nonalcoholic Steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150:1147-1159.e1145.
15. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956-965.
16. Friedman SL, Ratziu V, Harrison SA, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2018;67:1754-1767.
17. Loomba R, Lawitz E, Mantry PS, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology (Baltimore, Md). 2018;67:549-559.
18. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016; 387:679-690.
19. Spitzer AL, Lao OB, Dick AA, et al. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl. 2010;16: 874-884.
20. Dutkowski P, Schlegel A, Slankamenac K, et al. The use of fatty liver grafts in modern allocation systems: risk assessment by the balance of risk (BAR) score. Ann Surg. 2012;256:861-868; discussion 868-869.
21. Andert A, Ulmer TF, SchoningW, et al. Grade of donor liver microvesicular steatosis does not affect the postoperative outcome after liver transplantation. Hepatobiliary Pancreat Dis Int. 2017;16:617-623.
22. Halon A, Patrzalek D, Rabczynski J. Hepatic steatosis in liver transplant donors: rare phenomenon or common feature of donor population? Transplant Proc. 2006;38:193-195.
23. Deroose JP, Kazemier G, Zondervan P, et al. Hepatic steatosis is not always a contraindication for cadaveric liver transplantation. HPB (Oxford). 2011;13:417-425.
24. Doyle MB, Vachharajani N, Wellen JR, et al. Short-and long-term outcomes after steatotic liver transplantation. Arch Surg. 2010;145:653-660.
25. Angele MK, Rentsch M, Hartl WH, et al. Effect of graft steatosis on liver function and organ survival after liver transplantation. Am J Surg. 2008; 195:214-220.
26. Nasralla D, Coussios CC, Mergental H, et al. A randomized trial of normothermic preservation in liver transplantation. Nature. 2018;557:50-56.
27. Treckmann J, Minor T, Saad S, et al. Retrograde oxygen persufflation preservation of human livers: a pilot study. Liver Transpl. 2008;14:358-364.
28. Kron P, Schlegel A, Mancina L, et al. Hypothermic oxygenated perfusion (HOPE) for fatty liver grafts in rats and humans. J Hepatol. 2017;S0168-8278(17)32268-7.
29. He X, Guo Z, Zhao Q, et al. The first case of ischemia-free organ transplantation in humans: a proof of concept. Am J Transplant. 2018;18:737-744.
30. Minor T, Pütter C, Gallinat A, et al. Oxygen persufflation as adjunct in liver preservation (OPAL): study protocol for a randomized controlled trial. Trials. 2011;12:234.
31. Amano Y, Tsuchiya S, Imai M, et al. Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis. Biochem Biophys Res Commun. 2018; 497:207-213.
32. Yang H, Suh DH, Kim DH, et al. Metabolomic and lipidomic analysis of the effect of pioglitazone on hepatic steatosis in a rat model of obese type 2 diabetes. Br J Pharmacol. 2018.
33. Toriniwa Y, Saito T, Miyajima K, et al. Investigation of pharmacological responses to anti-diabetic drugs in female spontaneously diabetic Torii (SDT) fatty rats, a new nonalcoholic steatohepatitis (NASH) model. J Vet Med Sci. 2018;80:878-885.
34. Deng W, Meng Z, Sun A, et al. Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: evidence fromin vitro study. Cancer Biomark. 2017;20:411-415.
35. van der Veen JN, Lingrell S, Gao X, et al. Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice. Am J Physiol Gastrointest Liver Physiol. 2016;310: G526-G538.
36. Hayashizaki-Someya Y, Kurosaki E, Takasu T, et al. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. Eur J Pharmacol. 2015;754:19-24.
37. ZhangW,Wu R, Zhang F, et al. Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway. Clin Exp Pharmacol Physiol. 2012;39:1026-1033.
38. SchaalanMF. Effects of pioglitazone and/or simvastatin on circulating TNF and adiponectin levels in insulin resistance. J Immunotoxicol. 2012;9:201-209.
39. Pita J, Panadero A, Soriano-Guillén L, et al. The insulin sensitizing effects of PPAR-agonist are associated to changes in adiponectin index and adiponectin receptors in Zucker fatty rats. Regul Pept. 2012;174:18-25.
40. Fujimoto M, Tsuneyama K, Kainuma M, et al. Evidence-based efficacy of Kampo formulas in amodel of non alcoholic fatty liver. ExpBiolMed (Maywood). 2008;233:328-337.
41. Nan YM,WuWJ, Fu N, et al. Antioxidants Vitamin E and 1-aminobenzotriazole prevent experimental non-alcoholic steatohepatitis in mice. Scand J Gastroenterol. 2009;44:1121-1131.
42. Mells JE, Fu PP, Sharma S, et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a western diet. Am J Physiol Gastrointest Liver Physiol. 2012;302:G225-G235.
43. Sharma S, Mells JE, Fu PP, et al. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One. 2011;6:e25269.
44. Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013;58:1941-1952.
45. Tølbøl KS, Kristiansen MN, Hansen HH, et al. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J Gastroenterol. 2018;24:179-194.
46. Fiorucci S, Antonelli E, Rizzo G, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology. 2004;127:1497-1512.
47. Fiorucci S, Rizzo G, Antonelli E, et al.Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther. 2005;315:58-68.
48. Verbeke L, Mannaerts I, Schierwagen R, et al. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Sci Rep. 2016;6:33453.
49. Goto T, Itoh M, Suganami T, et al. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis. Sci Rep. 2018;8:8157.
50. Lefebvre E, Moyle G, Reshef R, et al. Antifibrotic effects of the dual CCR2/ CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One. 2016;11:e0158156.
51. Krenkel O, Puengel T, Govaere O, et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology. 2018;67:1270-1283.
52. He P, Zeng B, Zhang XL, et al. Protective effect of apoptosis signal-regulating kinase 1 inhibitor against mice liver injury. Asian Pac J Trop Med. 2016;9: 283-287.
53. Budas G, Karnik S, Jonnson T, et al. Reduction of liver steatosis and fibrosis with an Ask1 inhibitor in a murine model of NASH is accompanied by improvements in cholesterol, bile acid and lipid metabolism. J Hepatol. 2016;64:S170.
54. Ikenaga N, Liu S, Peng Z, et al. Dual combination therapy directed against lysyloxidase-like 2 (LOXL2) and apoptosis signal-regulating kinase 1(ASK1) potently inhibits fibrosis and portal hypertension in a new mouse model of PSC-like liver disease/NASH [abstract]. Hepatology. 2015;62(Suppl):881A.
55. Liles JT, Zagorska A, Hollenback D, et al. Combination of an ASK1 inhibitor and FXR agonist increases efficacy in a mouse model of non-alcoholic steatohepatitis. J Hepatol. 2017;66:S19-S20.
56. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis andmanagement of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592-1609.
57. Fiorucci S, Biagioli M, Distrutti E. Future trends in the treatment of non-alcoholic steatohepatitis. Pharmacol Res. 2018;134:289-298.
58. Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol. 2015;62(1 Suppl):S65-S75.
59. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002;51:2968-2974.
60. Ratziu V, Charlotte F, Bernhardt C, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology. 2010;51:445-453.
61. Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology. 2007; 46:424-429.
62. Boettcher E, Csako G, Pucino F, et al. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2012;35:66-75.
63. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2012;56:255-266.
64. Glass LM, Dickson RC, Anderson JC, et al. Total body weight loss of 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2015;60:1024-1030.
65. Hannah WN Jr, Harrison SA. Lifestyle and dietary interventions in the management of nonalcoholic fatty liver disease. Dig Dis Sci. 2016;61: 1365-1374.
66. Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137:532-540.
67. Bower G, Toma T, Harling L, et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg. 2015;25:2280-2289.
68. Musso G, Cassader M, Paschetta E, et al. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med. 2017;177:633-640.
69. Sato K, Gosho M, Yamamoto T, et al. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutrition. 2015;31:923-930.
70. Xu R, Tao A, Zhang S, et al. Association between Vitamin E and nonalcoholic steatohepatitis: a meta-analysis. Int J Clin Exp Med. 2015;8: 3924-3934.
71. Li J, Liu B, Yan LN, et al. Reversal of graft steatosis after liver transplantation: prospective study. Transplant Proc. 2009;41:3560-3563.
72. Chavin KD, Taber DJ, Norcross M, et al. Safe use of highly steatotic livers by utilizing a donor/recipient clinical algorithm. Clin Transplant. 2013;27: 732-741.
73. Gabrielli M, Moisan F, Vidal M, et al. Steatotic livers. Can we use them in OLTX? Outcome data from a prospective baseline liver biopsy study. Ann Hepatol. 2012;11:891-898.
74. de Graaf EL, Kench J, Dilworth P, et al. Grade of deceased donor liver macrovesicular steatosis impacts graft and recipient outcomes more than the donor risk index. J Gastroenterol Hepatol. 2012;27:540-546.
75. Noujaim HM, de Ville de Goyet J, Montero EF, et al. Expanding postmortem donor pool using steatotic liver grafts: a new look. Transplantation. 2009;87:919-925.
76. Gao F, Xu X, Ling Q, et al. Efficacy and safety ofmoderately steatotic donor liver in transplantation. Hepatobiliary Pancreat Dis Int. 2009;8:29-33.
77. Burra P, Loreno M, Russo FP, et al. Donor liverswith steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl. 2009;15:619-628.
78. Wong TC, Fung JY, Chok KS, et al. Excellent outcomes of liver transplantation using severely steatotic grafts from brain-dead donors. Liver Transpl. 2016;22:226-236.
79. Sharkey FE, Lytvak I, Prihoda TJ, et al. High-grade microsteatosis and delay in hepatic function after orthotopic liver transplantation. Hum Pathol. 2011;42:1337-1342.
80. Baccarani U, Adani GL, Isola M, et al. Steatosis of the graft is a risk factor for posttransplantation biliary complications. Transplant Proc. 2009;41:1313-1315.
81. Echeverri J, Goldaracena N, Kaths JM, et al. Comparison of BQ123, epoprostenol, and verapamil as vasodilators during normothermic ex vivo liver machine perfusion. Transplantation. 2018;102:601-608.
82. Selzner M, Goldaracena N, Echeverri J, et al. Normothermic ex vivo liver perfusion using Steen solution as perfusate for human liver transplantation: first North American results. Liver Transpl. 2016;22: 1501-1508.
83. Liu Q, Berendsen T, Izamis ML, et al. Perfusion defatting at subnormothermic temperatures in steatotic rat livers. Transplant Proc. 2013;45:3209-3213.
84. Nagai K, Yagi S, Afify M, et al. Impact of venous-systemic oxygen persufflation with nitric oxide gas on steatotic grafts after partial orthotopic liver transplantation in rats. Transplantation. 2013;95:78-84.
85. Boncompagni E, Gini E, Ferrigno A, et al. Decreased apoptosis in fatty livers submitted to subnormothermic machine-perfusion respect to cold storage. Eur J Histochem. 2011;55:e40.
86. Jamieson RW, Zilvetti M, Roy D, et al. Hepatic steatosis and normothermic perfusion-preliminary experiments in a porcine model. Transplantation. 2011;92:289-295.
87. Ye S, Dong J, Han B. Protective effect of reduced glutathione and venous systemic oxygen persufflation on rat steatotic graft following liver transplantation. J Surg Res. 2010;158:138-146.
88. Minor T, Stegemann J, Hirner A, et al. Impaired autophagic clearance after cold preservation of fatty livers correlates with tissue necrosis upon reperfusion and is reversed by hypothermic reconditioning. Liver Transpl. 2009; 15:798-805.
89. Vairetti M, Ferrigno A, Carlucci F, et al. Subnormothermic machine perfusion protects steatotic livers against preservation injury: a potential for donor pool increase? Liver Transpl. 2009;15:20-29.
90. Bessems M, Doorschodt BM, Kolkert JL, et al. Preservation of steatotic livers: a comparison between cold storage andmachine perfusion preservation. Liver Transpl. 2007;13:497-504.
91. Minor T, Akbar S, Tolba R, et al. Cold preservation of fatty liver grafts: prevention of functional and ultrastructural impairments by venous oxygen persufflation. J Hepatol. 2000;32:105-111.
92. Liu Q, Nassar A, Buccini L, et al. Lipid metabolism and functional assessment of discarded human livers with steatosis undergoing 24 hours of normothermic machine perfusion. Liver Transpl. 2018;24:233-245.
93. Vogel T, Brockmann JG, Quaglia A, et al. The 24-hour normothermic machine perfusion of discarded human liver grafts. Liver Transpl. 2017;23: 207-220.
94. Banan B, Watson R, Xu M, et al. Development of a normothermic extracorporeal liver perfusion system toward improving viability and function of human extended criteria donor livers. Liver Transpl. 2016;22:979-993.
95. Bruinsma BG, Sridharan GV, Weeder PD, et al. Metabolic profiling during ex vivo machine perfusion of the human liver. Sci Rep. 2016;6:22415.
96. Gallinat A, Hoyer DD, Klein C, et al. In house oxygen persufflation of cold stored livers versus simple cold storage in extended criteria liver grafts: 5-year results of a randomized controlled clinical trial. Transplantation. 2018;102:S381.
97. Nagrath D, Xu H, Tanimura Y, et al. Metabolic preconditioning of donor organs: defatting fatty livers by normothermic perfusion ex vivo. Metab Eng. 2009;11:274-283.
98. Sutton ME, op den Dries S, Karimian N, et al. Criteria for viability assessment of discarded human donor livers during ex vivo normothermic machine perfusion. PLoS One. 2014;9:e110642.
99. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468-475.